Illumina announces strategy to accelerate value creation

Core Insights - Illumina is poised to accelerate revenue growth into high single digits over the next three years, driven by its core genomics portfolio [1][4] - The company aims to deliver double-digit to teens non-GAAP diluted earnings per share growth from 2025 to 2027 [1][4] - A new research partnership with the Broad Institute of MIT and Harvard has been announced to advance single-cell sequencing [1][2] Revenue and Earnings Growth - Illumina expects to achieve high single-digit revenue growth by 2027, leveraging operational efficiencies and significant free cash flow [4] - The company is focused on a systematic and disciplined approach to allocate its free cash flow to enhance profitability [4] Innovations and Technology - Illumina plans to introduce new innovations that will redefine genome analysis and provide deeper biological insights through multiomics [2][3] - The company is developing scalable growth businesses that complement its high-throughput sequencing franchise [3] - Innovations include novel sample preparation, integrated software, and complete multiomic workflows to enhance laboratory operations [3] Strategic Partnerships - The partnership with the Broad Institute aims to enable billion-cell experiments and accelerate the adoption of high-capacity single-cell experiments [2][3] - Collaborative efforts will focus on the development and validation of new kits for large-scale CRISPR screening [2][3]